MX2018015108A - Metodos para tratar la osificacion heterotopica. - Google Patents

Metodos para tratar la osificacion heterotopica.

Info

Publication number
MX2018015108A
MX2018015108A MX2018015108A MX2018015108A MX2018015108A MX 2018015108 A MX2018015108 A MX 2018015108A MX 2018015108 A MX2018015108 A MX 2018015108A MX 2018015108 A MX2018015108 A MX 2018015108A MX 2018015108 A MX2018015108 A MX 2018015108A
Authority
MX
Mexico
Prior art keywords
methods
heterotopic ossification
reduce
flare
ups
Prior art date
Application number
MX2018015108A
Other languages
English (en)
Inventor
Desjardins Clarissa
Roy Grogan Donna
Neal Packman Jeffrey
Harnett Mark
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of MX2018015108A publication Critical patent/MX2018015108A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención presenta regímenes de dosificación y formulaciones farmacéuticas para la administración oral de palovaroteno. Los regímenes de dosificación pueden reducir la osificación heterotópica, reducir el número de brotes y/o reducir la gravedad de los brotes en sujetos que sufren de fibrodisplasia osificante progresiva.
MX2018015108A 2016-06-08 2017-06-08 Metodos para tratar la osificacion heterotopica. MX2018015108A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347381P 2016-06-08 2016-06-08
PCT/CA2017/050701 WO2017210792A1 (en) 2016-06-08 2017-06-08 Methods for treating heterotopic ossification

Publications (1)

Publication Number Publication Date
MX2018015108A true MX2018015108A (es) 2019-08-29

Family

ID=60578331

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015108A MX2018015108A (es) 2016-06-08 2017-06-08 Metodos para tratar la osificacion heterotopica.
MX2022001991A MX2022001991A (es) 2016-06-08 2018-12-05 Metodos para tratar la osificacion heterotopica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001991A MX2022001991A (es) 2016-06-08 2018-12-05 Metodos para tratar la osificacion heterotopica.

Country Status (17)

Country Link
US (3) US10864194B2 (es)
EP (2) EP4249490A3 (es)
JP (2) JP7023868B2 (es)
KR (1) KR102486607B1 (es)
CN (1) CN109562099A (es)
AU (2) AU2017276835B2 (es)
BR (1) BR112018075422A2 (es)
CA (1) CA3025854A1 (es)
CL (1) CL2018003502A1 (es)
EA (1) EA201892497A1 (es)
ES (1) ES2963348T3 (es)
IL (2) IL295440A (es)
MX (2) MX2018015108A (es)
PH (1) PH12018502563A1 (es)
SG (1) SG11201810658PA (es)
WO (1) WO2017210792A1 (es)
ZA (1) ZA201808102B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
EA201892497A1 (ru) * 2016-06-08 2019-05-31 Клементиа Фармасьютикалз Инк. Способы лечения гетеротопической оссификации
CN110381939B (zh) * 2016-11-16 2022-12-02 同理制药公司 用于治疗多发性骨软骨瘤(mo)的方法
WO2020118405A1 (en) * 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
WO2021249240A1 (zh) * 2020-06-11 2021-12-16 养生堂有限公司 Palovarotene在抗hbv病毒治疗中的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2001068135A2 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
JP4118675B2 (ja) 2000-10-02 2008-07-16 エフ．ホフマン−ラ ロシュ アーゲー 気腫治療用新規レチノイド
JP4421293B2 (ja) 2001-09-18 2010-02-24 エフ．ホフマン−ラ ロシュ アーゲー アルキル尿素レチノイドアゴニストｉ
MXPA04002305A (es) 2001-09-18 2004-06-29 Hoffmann La Roche Agonistas ii de retinoides de urea sustituida.
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
EP1868576A2 (en) 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
KR20080089512A (ko) * 2006-01-26 2008-10-06 콤비네이토릭스, 인코포레이티드 근골격계 질환 및 이와 관련된 증상을 치료하기 위한 방법,조성물 및 키트
WO2007113122A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
CA2651487A1 (en) 2006-05-16 2007-11-29 Vitae Pharmaceuticals, Inc. Methods for treating chemotherapy and radiation therapy side effects
CN101687031B (zh) 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) * 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
US20120121546A1 (en) 2009-02-05 2012-05-17 Vishal Bhasin Method of Producing Progenitor Cells from Differentiated Cells
WO2011011513A1 (en) * 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
CN103702967A (zh) 2011-03-14 2014-04-02 貝丝以色列女执事医疗中心 用于治疗增殖性病症的方法和组合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20140220154A1 (en) * 2011-07-01 2014-08-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service Method of treating pathologic heterotopic ossification
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
EP2900238B1 (en) 2012-09-28 2017-12-06 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
JP2016510745A (ja) * 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
KR102303316B1 (ko) 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제
WO2016054406A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) * 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
EA201892497A1 (ru) * 2016-06-08 2019-05-31 Клементиа Фармасьютикалз Инк. Способы лечения гетеротопической оссификации

Also Published As

Publication number Publication date
EA201892497A1 (ru) 2019-05-31
IL263440B (en) 2022-09-01
KR102486607B1 (ko) 2023-01-11
EP3468554C0 (en) 2023-08-09
CA3025854A1 (en) 2017-12-14
US11622959B2 (en) 2023-04-11
CL2018003502A1 (es) 2019-04-26
ES2963348T3 (es) 2024-03-26
KR20190017883A (ko) 2019-02-20
US20230285360A1 (en) 2023-09-14
EP4249490A2 (en) 2023-09-27
EP3468554A1 (en) 2019-04-17
EP3468554B1 (en) 2023-08-09
PH12018502563A1 (en) 2019-10-14
IL295440A (en) 2022-10-01
AU2022202148B2 (en) 2023-08-24
SG11201810658PA (en) 2018-12-28
AU2017276835A1 (en) 2018-12-13
MX2022001991A (es) 2022-03-11
EP4249490A3 (en) 2023-12-13
BR112018075422A2 (pt) 2019-03-12
US10864194B2 (en) 2020-12-15
AU2017276835B2 (en) 2022-03-31
EP3468554A4 (en) 2020-01-22
WO2017210792A1 (en) 2017-12-14
JP2022019995A (ja) 2022-01-27
CN109562099A (zh) 2019-04-02
US20210069152A1 (en) 2021-03-11
IL263440A (en) 2019-01-31
US20190216781A1 (en) 2019-07-18
ZA201808102B (en) 2024-04-24
JP2019517528A (ja) 2019-06-24
JP7023868B2 (ja) 2022-02-22
AU2022202148A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
PH12018502563A1 (en) Methods for treating heterotopic ossification
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
CL2020001852A1 (es) Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)
NZ737399A (en) Ccr2 modulators
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GB2541571A (en) Pharmaceutical compositions
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
DK3484502T3 (da) Blodplasmafraktioner til behandling mod aldersrelaterede kognitive forstyrrelser
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2017006692A (es) Trastornos neurodegenerativos.
DK3773595T3 (da) Farmaceutiske anticancer-sammensætninger til kombineret terapi